Haloperidol Versus Atypical Antipsychotics for Delirium in Hospitalized and ICU Patients: A Systematic Review and Meta-analysis
Authors:
- Murilo Marmori CruccioliMCMurilo Marmori Cruccioli
- Pedro Henrique Teixeira CarneiroPCPedro Henrique Teixeira Carneiro
- Jorge Ferreira Jasmineiro PitangaJPJorge Ferreira Jasmineiro Pitanga
- Camila Carneiro FerreiraCFCamila Carneiro Ferreira
- Regina Carneiro LeãoRLRegina Carneiro Leão
- Milena Lima LouresMLMilena Lima Loures
- Caio Rezende LimaCLCaio Rezende Lima
- Pedro FraimanPFPedro Fraiman
- Filipe P. SarmentoFSFilipe P. Sarmento
- 27 August 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Abstract
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.Keywords
This publication has 27 references indexed in Scilit:
- Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium: Randomized Controlled TrialNeurocritical Care, 2024
- Antipsychotics and the QTc Interval During Delirium in the Intensive Care UnitJAMA Network Open, 2024
- DeliriumNature Reviews Disease Primers, 2020
- Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the LiteraturePsychosomatics, 2019
- Consensus and variations in opinions on delirium care: a survey of European delirium specialistsInternational Psychogeriatrics, 2013
- Comparative efficacy study of haloperidol, olanzapine and risperidone in deliriumJournal of Psychosomatic Research, 2011
- A Double-Blind Trial of Risperidone and Haloperidol for the Treatment of DeliriumPsychosomatics, 2004
- Olanzapine vs haloperidol: treating delirium in a critical care settingIntensive Care Medicine, 2003
- Underlying Pathologies and Their Associations With Clinical Features in Terminal Delirium of Cancer PatientsJournal of Pain and Symptom Management, 2001
- Delirium (Acute Confusional States)JAMA, 1987